In pancreatic cancer, the coexistence of “tumor‐promoting” FAP+ CAFs and “tumor‐suppressing”α‐SMA+ CAFs highlights the complexity of CAF‐targeted therapies. This evidence concerns the gene FAP and neoplasm.